The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2015 | An update on the phase 3 MDS-005 trial
Valeria Santini
• 11 Jun 2015
At the 20th Congress of the European Hematology Association (EHA), Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses the phase 3 MDS-005 trial, which evaluated the impact of baseline erythropoietin levels on red blood cell (RBC)-transfusion independence in lenalidomide-treated patients with low or intermediate-1-risk myelodysplastic syndromes without deletion 5q.
